5 Stocks Pushing The Health Services Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 115 points (-0.8%) at 13,894 as of Monday, Feb. 4, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 654 issues advancing vs. 2,230 declining with 132 unchanged.

The Health Services industry currently sits down 0.9% versus the S&P 500, which is down 0.9%. On the negative front, top decliners within the industry include Thermo Fisher Scientific ( TMO), down 2.6%, Life Technologies ( LIFE), down 2.2%, Waters Corporation ( WAT), down 2.3%, Stryker Corporation ( SYK), down 1.3% and DaVita HealthCare Partners ( DVA), down 1.2%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Covidien ( COV) is one of the companies pushing the Health Services industry lower today. As of noon trading, Covidien is down $0.38 (-0.6%) to $62.26 on light volume Thus far, 636,987 shares of Covidien exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $62.06-$62.61 after having opened the day at $62.25 as compared to the previous trading day's close of $62.65.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $29.4 billion and is part of the health care sector. The company has a P/E ratio of 16.0, below the S&P 500 P/E ratio of 17.7. Shares are up 8.0% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Covidien a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, solid stock price performance, reasonable valuation levels, good cash flow from operations and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Covidien Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback